YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

Rhea-AI Summary

YD Bio (Nasdaq: YDES) exhibited at the 9th Healthcare Expo Taiwan in Taipei from Dec 4–7, 2025, presenting its DNA methylation-based OkaiDx cancer detection platform, multi-biomarker early detection, next-generation precision diagnostics, and ophthalmology stem cell/exosome programs at Booth No. 4F, M1004.

The company reported 1,500+ visitors and 541 on-site surveys over four days, held discussions with distributors from China, Hong Kong, Indonesia, and Dubai, and engaged hospital leaders about using EG BioMed US Inc.'s CLIA-certified, CAP-accredited U.S. lab as a global central lab for precision cancer testing.

Key Figures

Expo visitors 1,500+ visitors 9th Healthcare Expo Taiwan, December 4–7, 2025

On-site surveys 541 surveys Collected over 4 days at Booth No. 4F, M1004

PDAC sensitivity (early) 93.8% sensitivity Early-stage (I–II) pancreatic cancer detection study (100 PDAC / 500 controls)

PDAC specificity 97.3% specificity Healthy control group in EG BioMed PDAC study

PDAC overall accuracy 97.7% accuracy EG BioMed PDAC early detection dataset

Breast test accuracy 95.1% accuracy Independent validation of OkaiDx™ cfDNA-methylation breast monitoring test

Public Warrants registered 11,500,000 shares Ordinary shares issuable upon exercise of Public Warrants

Shares outstanding 70,521,359 shares Ordinary shares outstanding as of October 22, 2025

Market Reality Check

$12.64 Last Close

Volume Volume 125,715 is 1.32x the 20-day average of 95,036, indicating elevated interest ahead of this expo update. normal

Technical Price 15.42 is trading above the 200-day MA at 14.99, reflecting a constructive longer-term trend pre‑news.

Peers on Argus

YDES gained 10.9% while key biotech peers were mixed: BHVN up 8.21%, ABCL, JANX, PHVS and SNDX down between 0.96% and 5.41%, pointing to a stock-specific move rather than a sector-wide swing.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 02	Clinical performance data	Positive	+3.7%	Reported strong OkaiDx™ pancreatic cancer sensitivity, specificity and accuracy in U.S. study.
Nov 24	Ophthalmology milestone	Positive	+4.5%	Announced U.S. ophthalmology entry with FDA 510(k) clearance and OTC-compliant eye products.
Nov 05	Product access expansion	Positive	-3.1%	Expanded OkaiDx™ breast cancer monitoring access via CLIA/CAP lab as RUO assay.
Oct 20	Nasdaq listing event	Positive	-0.9%	Celebrated Nasdaq listing intended to support commercialization and long-term growth plans.
Oct 10	Lab accreditation	Positive	-7.0%	Partner EG BioMed gained CAP accreditation, bolstering U.S. cancer detection capabilities.

Pattern Detected

Recent YDES news often drew mixed reactions: some positive clinical and regulatory milestones aligned with gains, while several seemingly favorable operational updates coincided with price declines, suggesting inconsistent news-to-price translation.

Recent Company History

Over the last few months, YDES has reported multiple milestones across diagnostics and ophthalmology. On Oct 10, 2025, a partner’s CAP accreditation supported U.S. cancer detection programs, followed by the Nasdaq listing celebration on Oct 20, 2025. Subsequent news expanded OkaiDx™ access and launched U.S. ophthalmology products with FDA 510(k) clearance and OTC compliance. A Dec 2, 2025 update highlighted strong pancreatic cancer test performance. Today’s expo-focused announcement fits this pattern of showcasing technology and commercialization progress.

Market Pulse Summary

The stock dropped -18.4% in the session following this news. A negative reaction despite promotional and partnering news would fit prior instances where seemingly favorable milestones, such as CAP accreditation on Oct 10, 2025 or the Nasdaq listing on Oct 20, 2025, coincided with price declines. Investors have previously focused on overhang from registered shares and warrants, as described in recent prospectus filings. Any renewed concern around dilution or commercialization timelines could overshadow conference-related enthusiasm.

Key Terms

dna methylation medical

"a biotechnology company advancing DNA methylation-based cancer detection technology"

A chemical tag added to DNA that acts like a sticky note on a recipe, changing whether a gene is read without altering the underlying genetic code. For investors, DNA methylation matters because these tags can serve as measurable biomarkers for disease diagnosis, risk prediction, and treatment response, and they can be targets for drugs or diagnostic tests—factors that influence clinical value, regulatory approval, and market potential.

multi-biomarkers medical

"early cancer detection powered by DNA methylation and multi-biomarkers"

Multi-biomarkers are a set of biological signals—such as proteins, genes, or blood chemicals—measured together to give a more complete picture of a disease or patient response than any single measure alone. For investors, multi-biomarker tests matter because they can improve diagnostic accuracy, guide treatment decisions, reduce costly trial failures, and therefore increase the commercial value and regulatory appeal of diagnostics, drugs, or medical technologies—think of several gauges on a dashboard rather than one.

precision diagnostics medical

"next-generation precision diagnostics and stem cell therapy & exosome platforms"

Precision diagnostics are medical tests that go beyond yes/no answers to identify specific characteristics of a patient’s condition—such as genetic changes, precise disease subtypes, or markers that predict how someone will respond to a treatment. Like a high-resolution map guiding a mechanic to the exact part that needs fixing, these tests help doctors choose the most effective therapies and avoid ineffective ones. For investors, precision diagnostics matter because they can drive demand for targeted treatments, create partnerships with drug makers, influence reimbursement decisions, and often command higher prices than one-size-fits-all tests.

stem cell therapy medical

"next-generation precision diagnostics and stem cell therapy & exosome platforms"

Therapies that use special cells capable of becoming different tissue types to repair, replace, or support damaged organs and systems—think of them as tiny seeds planted to regrow or fix parts of the body. Investors care because successful stem cell therapies can create entirely new markets or transform treatment costs, but they also carry long development timelines, high research and regulatory risk, and uncertain commercial returns until proven safe and effective.

exosome platforms medical

"stem cell therapy & exosome platforms focused on ophthalmology conditions"

Exosome platforms are technologies that create, modify or analyze tiny biological packets cells naturally send to communicate, used to carry drugs or detect disease markers. For investors, they matter because a well-developed platform can turn a scientific idea into many products—like a factory that can make different medicines or tests—potentially scaling revenue, but they also bring development, manufacturing and regulatory risks that can affect valuation and timelines.

clia-certified regulatory

"EG BioMed US Inc.’s CLIA-certified and CAP-accredited laboratory in the United States"

CLIA-certified means a laboratory has passed U.S. federal standards for performing tests on human samples, showing its results are accurate, reliable and timely. For investors this matters because certification is often required to sell clinical test services, bill insurers, win hospital or physician partnerships and avoid regulatory penalties — much like a restaurant passing a health inspection or a car getting a safety sticker before it can be sold.

cap-accredited regulatory

"CLIA-certified and CAP-accredited laboratory in the United States as a global central lab"

Cap-accredited means a laboratory or diagnostic service has been inspected and certified by the College of American Pathologists (CAP) for meeting rigorous standards in testing accuracy, quality control, staff qualifications and reporting. For investors, CAP accreditation signals that the lab’s results are more reliable and that the operation meets a well-recognized regulatory benchmark, which can reduce clinical and regulatory risk and support market trust and reimbursement; think of it like a high-score health inspection for a restaurant.

central lab technical

"laboratory in the United States as a global central lab for delivering precision cancer testing"

A central lab is a single, specialized laboratory chosen to process and analyze clinical trial samples from many study sites so results are consistent and comparable. Like using the same kitchen to prepare dishes for a food competition rather than many home cooks, it reduces variation and errors, helps meet regulatory standards, and can speed or slow trial timelines—factors that affect costs, development risks, and the reliability of data investors rely on.

AI-generated analysis. Not financial advice.

Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its successful participation in the prestigious 9th Healthcare Expo Taiwan, which was held from December 4-7, 2025, at TaipeiNEX 1. The Company exhibited at Booth No. 4F, M1004, where it presented its latest advances in three core portfolios: early cancer detection powered by DNA methylation and multi-biomarkers, next-generation precision diagnostics and stem cell therapy & exosome platforms focused on ophthalmology conditions. With 1,500+ visitors and 541 on-site surveys in 4 days, this significant event served as a critical gateway for YD Bio to connect with key stakeholders, explore new market opportunities globally, and reinforce its position as an innovator in the world’s healthcare landscape, providing an unparalleled platform to engage with leading hospitals, tech giants, and biotech innovators from across the region and beyond.

YD Bio Meets Industry Peers at Healthcare Expo Taiwan, Celebrates Successful Exhibition

The Company believes that its innovative product offerings, including its advanced ophthalmologic solutions and the expanded OkaiDx^™ cancer detection platform, garnered significant attention and positive feedback from attendees. This successful engagement underscores YD Bio’s role as a pioneer in cancer detection and therapeutic innovation and provided valuable opportunities for networking and showcasing its latest advancements to a broad audience of industry professionals, potential partners, and investors.

During the four-day exhibition, YD Bio also engaged in productive discussions with multiple international distributors from China, Hong Kong, Indonesia, and Dubai, all of whom expressed strong interest in collaborating to introduce and expand the Company’s cancer detection and ophthalmologic product portfolios within their respective markets. These engagements represent a key advancement in YD Bio’s global commercialization strategy, opening new channels for OkaiDx^™ and other cancer detection innovations in high-growth regions.

The Company met with numerous key opinion leaders, hospital executives, and healthcare decision-makers from major hospitals across Asia to discuss the utilization of EG BioMed US Inc.’s CLIA-certified and CAP-accredited laboratory in the United States as a global central lab for delivering precision cancer testing services, along with the regulatory and compliance requirements across different countries. These conversations created substantial opportunities to broaden the clinical adoption of OkaiDx^™ blood-based cancer detection tests within hospitals, medical centers, and healthcare systems worldwide.

The Company believes the strong interest from international stakeholders highlights the accelerating global demand for advanced early-detection and cancer treatment-monitoring technologies and reinforces YD Bio’s commitment to expanding global access to precision cancer detection and preventive healthcare solutions. Collectively, these interactions underscore the 9th Healthcare Expo Taiwan as a pivotal platform for advancing YD Bio’s international presence and strengthening collaborations that support large-scale clinical deployment of next-generation cancer detection technologies.

"We were thrilled to participate in the 9th Healthcare Expo Taiwan, an essential gathering for the global healthcare community and a pivotal event for our Company," said Dr. Ethan Shen, Chairman and CEO of the Company, commented. "This expo provided an exceptional opportunity to showcase our latest advancements to a diverse international audience. We are dedicated to a pragmatic path from development to revenue within a large, needs-based category, and we look forward to engaging with partners and professionals who share our vision for a healthier future."

YD Bio extends its gratitude to all attendees who visited Booth No. 4F, M1004, to discuss potential partnerships, and meet the dedicated team advancing healthcare innovation. The Company expresses its appreciation for the engaging discussions and valuable connections made during the event.

About YD Bio Limited

YD Bio Limited is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and limbal stem cell and exosome therapies with the potential to transform the treatment of diseases with high unmet medical need. The Company is committed to improving patient outcomes through scientific innovation and precision medicine. In addition to its R&D efforts, YD Bio Limited is a recognized supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. For more information, please visit the Company’s website: ir.ydesgroup.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, YD Bio’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on YD Bio’s current expectations and projections about future events that YD Bio believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. YD Bio undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although YD Bio believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and YD Bio cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in YD Bio’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

FAQ

What did YD Bio (YDES) present at the 9th Healthcare Expo Taiwan on Dec 4–7, 2025?

YD Bio showcased its OkaiDx DNA methylation cancer detection platform, multi-biomarker early-detection tools, precision diagnostics, and ophthalmology stem cell/exosome platforms.

How many visitors and surveys did YD Bio record at the Healthcare Expo Taiwan 2025?

The company reported 1,500+ visitors and 541 on-site surveys during the four-day exhibition.

Which international markets did YD Bio engage with at the expo (YDES)?

YD Bio engaged with potential distributors from China, Hong Kong, Indonesia, and Dubai to discuss regional commercialization.

What laboratory did YD Bio discuss using as a global central lab for OkaiDx (YDES)?

YD Bio discussed using EG BioMed US Inc.'s CLIA-certified, CAP-accredited laboratory in the United States as a global central lab for precision cancer testing.

What commercialization opportunities did YD Bio highlight at Healthcare Expo Taiwan 2025?

The company highlighted opportunities for international distribution, hospital adoption, and broader clinical deployment of its blood-based cancer detection tests.